Oral Berotralstat Expanded Access Program

• Conditions: Hereditary Angioedema; HAE; Prophylaxis

• Registration Number: NCT04428632
• Lead Sponsor: BioCryst Pharmaceuticals

Brief Summary

This expanded access program will provide access to berotralstat for eligible participants with hereditary angioedema in the U.S.

Detailed Description

Physicians may request access to berotralstat for eligible participants with unmet medical need

Physicians can send email inquiries to access.us@inceptua.com or call 1-888-225-8677

Patients who may be interested should contact their physician about participation

Berotralstat (BCX7353) will be available through this expanded access program until it is commercially available

Study Timeline

• Study First Submitted: 2020-06-10
• Study First Submitted QC: 2020-06-10
• Study First Posted: 2020-06-11
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-09
• Last Update Posted: 2020-12-11

Recruitment & Eligibility

• Status: APPROVED_FOR_MARKETING
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified